Eli Lilly, Amylin Pharma, Alkermes Receive Complete Response Letter For Bydureon
Bydureon is the proposed brand name for Exenatide once weekly. It is an investigational, extended-release medication for type 2 diabetes designed to deliver continuous therapeutic levels of Exenatide
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.